ImmPACT Bio Appoints Ian Somaiya to Its Board of Directors
ImmPACT Bio Appoints Ian Somaiya to Its Board of Directors
LOS ANGELES, Aug. 14, 2024 /PRNewswire/ -- ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced the appointment of Ian Somaiya to its board of directors. Mr. Somaiya, currently chief financial officer (CFO) of NewAmsterdam Pharma Company N.V., brings more than 25 years of financial and operational leadership, including more than two decades on Wall Street as a prominent biotechnology research analyst.
2024年8月14日,美國ImmPACt Bio公佈新聞,任命Ian Somaiya擔任其董事會成員。ImmPACt Bio是一家處於臨床階段的生物製藥公司,正在開發新一代具有潛在變革性療效的細胞治療方案,旨在爲患者帶來積極的變化。Somaiya先生目前是NewAmsterdam Pharma Company N.V.的首席財務官,擁有25年以上的財務和運營領導經驗,包括在華爾街擔任傑出的生物技術研究分析師20年以上。
"Ian is an experienced executive with a deep understanding of the industry landscape and expertise in corporate strategy, financial planning and fundraising," said Sumant Ramachandra, M.D., Ph.D., chief executive officer of ImmPACT Bio. "We are pleased to welcome him to our board of directors where his guidance will be important as we continue to scale the company."
ImmPACt Bio的首席執行官Sumant Ramachandra萬.D., Ph.D.表示:「Ian是一位經驗豐富的高管,深刻理解行業趨勢,並擁有企業戰略,財務規劃和籌款方面的專業知識。」「我們很高興歡迎他加入我們的董事會,在企業擴張過程中,他的指導將非常重要。」Somaiya先生補充說:「ImmPACt Bio具有革新性的雙特異性CAR t細胞治療方案,有望在多種癌症和自身免疫性疾病的治療中發揮變革性作用。我期待加入ImmPACt Bio的董事會,並與團隊合作,進一步推進其臨床項目併發布預期的數據結果。」
Mr. Somaiya added, "ImmPACT Bio has the potential to make a transformative difference in the treatment of multiple cancers and autoimmune diseases with their innovative bispecific CAR T-cell therapies. I look forward to joining ImmPACT Bio's board and partnering with the team as they further advance their clinical programs with several anticipated data readouts."
Somaiya先生曾擔任高管領導職務,包括Elucida Oncology的首席財務官和首席業務官,他在該公司領導籌款和企業戰略,並擔任TCR2 Therapeutics的首席財務官,在該公司的首次公開招股及兩輪後續募資中引導公司,他已在華爾街工作了20年,是一名備受推崇的股票分析師,曾對100多家生物技術公司進行了廣泛的研究,涉及不同的治療領域,技術平台和發展階段。他曾是BMO Capital Markets生物技術研究主管,及Nomura Securities,Piper Jaffray和Thomas Weisel Partners的分析師。他在摩根士丹利和保德信證券擔任研究分析師,並因多年在生物技術報道中的優異表現被《華爾街日報》連續數年評爲「最佳行業分析師」。Somaiya先生還獲得了紐約大學生物學和神經科學學士學位。
Mr. Somaiya has held executive leadership positions, including CFO and chief business officer of Elucida Oncology, where he led fundraising and corporate strategy and, before that, as CFO of TCR2 Therapeutics, where he guided the company through its initial public offering and two subsequent follow-on offerings. Throughout his 20-year tenure on Wall Street, Mr. Somaiya was a highly esteemed equity analyst who conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms, and stages of development. He served as a managing director and head of biotechnology research at BMO Capital Markets and as managing director and equity analyst at Nomura Securities, Piper Jaffray, and Thomas Weisel Partners. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities and was recognized for several consecutive years as the "Best on the Street" by The Wall Street Journal for his biotechnology coverage. Mr. Somaiya received a B.A. in biology and neuroscience from New York University.
Somaiya先生已經擔任過多個高管領導職務,包括Elucida Oncology 的CFO和首席業務官,他領導籌款和公司戰略,並且之前還擔任過TCR2 Therapeutics的CFO,他引導公司完成了首次公開募股和兩次後續跟投。在華爾街任職20年期間,Somaiya先生是一位備受尊敬的股權分析師,他對100多家不同治療領域、技術平台和開發階段的生物技術公司進行了廣泛的研究。他曾擔任BMO Capital Markets的生物技術研究主管、Nomura Securities、Piper Jaffray和Thomas Weisel Partners的資深董事和股權分析師。他是作爲摩根士丹利和普天證券的研究分析師開啓他的華爾街生涯,並因爲對生物技術的覆蓋獲得連續數年的《華爾街日報》「最佳街頭」稱號。Somaiya先生獲得了紐約大學生物學和神經科學學士學位。
About ImmPACT Bio
ImmPACT Bio USA, Inc., is a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients. The company's logic-gate-based chimeric antigen receptor (CAR) T-cell therapies, licensed from University of California, Los Angeles (UCLA) Technology Development Group, are specifically designed to address antigen escape, reduce toxicity, overcome immunosupression in the tumor microenvironment, and improve cell persistence. The company's technology is based on the work of pioneering scientists, Yvonne Chen, Ph.D., and Antoni Ribas, M.D., Ph.D., both from UCLA. For more information, visit .
關於ImmPACt Bio
ImmPACt Bio USA,Inc.是一家處於臨床階段的生物製藥公司,正在開發新一代具有潛在變革性療效的細胞治療方案,旨在爲患者帶來積極的變化。該公司基於UCLA Technology Development Group授權,開發基於邏輯門的嵌合抗原受體(CAR)T細胞治療方案,旨在應對抗原逃逸,降低毒性,克服腫瘤微環境中的免疫抑制,並改善細胞持久性。該技術是UCLA的先驅科學家Yvonne Chen, Ph.D.和Antoni Ribas萬.D., Ph.D.的研究成果。欲知更多信息,請訪問該公司網站。
SOURCE ImmPACT Bio USA Inc.
來源:ImmPACt Bio USA Inc.